GLP-1 and Muscle Loss: The 2026 Evidence

Losing weight and staying strong are related goals, but they are not the same measurement. A lower number on the scale cannot tell you how much fat you lost, whether you are eating enough, or whether getting up from a chair has become harder.

The useful response to concerns about GLP-1 muscle loss is a plan for nutrition, resistance exercise and follow-up. It starts with understanding what the research actually measured.

Lean mass is not the same as skeletal muscle

Lean mass includes muscle and other nonfat soft tissue, including body water and organs. A DXA scan estimates body composition; a decrease in its lean-mass reading is not a direct measurement of lost skeletal muscle or reduced strength. The joint professional nutrition advisory recommends considering strength and function alongside body composition.

This distinction matters when a headline says that a percentage of weight loss was “muscle.” It also matters at home: a body-composition estimate is one piece of information, not a verdict on whether treatment is helping you.

What STEP 1 and SURMOUNT-1 found

These studies involved specific trial medicines and populations. Their findings do not establish the effects of compounded preparations.

Study	What was measured	Main finding	Important limit
STEP 1 exploratory DXA analysis	Body composition in 140 adults over 68 weeks, with semaglutide 2.4 mg weekly or placebo	Both fat and lean mass decreased; lean mass became a larger share of total body mass	A higher lean-mass percentage does not mean no lean tissue was lost
SURMOUNT-1 DXA substudy	Body composition in 160 adults over 72 weeks, with pooled tirzepatide doses or placebo	About 75% of weight lost was fat and 25% lean mass in both groups	Small substudy; an average ratio cannot predict an individual’s muscle strength or risk

Sources: STEP 1 body-composition analysis and SURMOUNT-1 body-composition study.

The SURMOUNT-1 substudy reported average reductions of 33.9% in fat mass and 10.9% in lean mass with tirzepatide. These are changes relative to each tissue’s starting amount, not percentages of the total weight lost. They should not be added together. The study helps describe body-composition changes; it does not prove that clinically important muscle loss is impossible or settle whether every patient has the same risk.

Semaglutide is a GLP-1 receptor agonist. This illustration explains the medicine’s identity; it does not depict muscle loss or predict a treatment result.

Build a food plan you can manage with less appetite

Adequate protein is part of muscle care, but it does not instruct the body to lose only fat. Total nutrition matters, and protein alone does not replace resistance training. The joint advisory emphasizes both.

Bring an ordinary day’s meals to your visit. Ask whether your plan supplies enough overall food and how to fit protein into portions you tolerate. Your target should account for medical history, including kidney disease, rather than come from a generic online calculator.

Practical ways to make that discussion concrete:

• Identify protein foods you already enjoy: eggs, fish, yogurt, tofu, beans or lentils.
• Keep an easy option available for busy days, such as yogurt or a bean soup.
• Note meals you repeatedly skip and symptoms that stop you eating.
• Ask whether a supplement would fill a specific gap before buying one.

Our semaglutide food guide includes meal examples and ways to discuss poor intake. If nausea is limiting food, use that as a reason to contact your clinician, not to push harder for faster weight loss.

Add strength work that fits your starting point

The U.S. physical activity guidelines recommend muscle-strengthening activity on at least two days each week for adults. That is general guidance, not a GLP-1-specific guarantee.

Resistance can come from bands, weights, machines or body-weight movements. A beginner might ask a professional to demonstrate a chair-based movement and a band exercise, then agree on a manageable starting routine. Someone already training can discuss how to adjust sessions when appetite or energy changes. Pain, balance problems and recent injuries deserve adaptations.

Walking is useful activity, but it should not be assumed to cover every strength goal. See semaglutide and exercise for questions to bring to a visit.

Monitor what you can do, as well as what you weigh

Choose a few everyday tasks to discuss at follow-up: climbing your usual stairs, carrying groceries, or getting out of a chair. Record whether they feel easier, unchanged or harder; these observations are not a diagnostic test.

Observation	What to bring to the care team
You are regularly too full to finish meals	A short food and symptom log, including missed meals
Strength or stamina seems to be declining	When it began, recent illness or inactivity, and what tasks changed
Exercise feels limited by pain or balance	Which movements cause problems and whether you need physical therapy
Weight is falling but daily life feels harder	The weight trend plus food intake, symptoms and functional changes

Older adults and people who begin treatment with low strength, frailty or limited intake merit particular attention. Ask whether baseline strength or body-composition assessment would help; there is no requirement that every person buy a scan. Joint advisory on assessment and muscle preservation.

Questions for your next appointment

• What nutrition target fits my health and how will we check that I can meet it?
• What strength activities are appropriate for me now?
• Which changes in daily function should prompt an earlier check-in?
• If eating becomes difficult, who should I contact before the next dose decision?
• How will we balance weight change with strength and quality of life?

Review REMEVi’s GLP-1 care information and medical team to prepare for that conversation. No program or supplement can promise complete muscle preservation.

This guide is educational and does not replace individual medical advice. FDA-approved products and compounded preparations are distinct: compounded drugs are not FDA-approved or reviewed for safety, effectiveness and quality before marketing. FDA information on unapproved GLP-1 drugs.